The CDO1 (Cysteine Dioxygenase Type 1) antibody is a tool used to detect the presence and expression levels of the CDO1 enzyme, which plays a critical role in sulfur amino acid metabolism. CDO1 catalyzes the oxidation of cysteine to cysteine sulfinic acid, a key step in taurine and sulfate biosynthesis, regulating cellular redox balance and detoxification. Dysregulation of CDO1 has been linked to various diseases, including cancer. Notably, CDO1 gene promoter hypermethylation, leading to reduced expression, is observed in multiple malignancies (e.g., colorectal, breast, and lung cancers), making it a potential epigenetic biomarker for early detection and prognosis.
CDO1 antibodies are typically monoclonal or polyclonal, validated for applications like immunohistochemistry (IHC), Western blotting, and ELISA. These antibodies aid in studying CDO1's tissue-specific expression patterns and its correlation with disease mechanisms. In research, CDO1 antibodies have helped elucidate its tumor-suppressive roles, such as modulating oxidative stress and inhibiting cancer cell proliferation. Commercial CDO1 antibodies are often characterized for specificity using knockout cell lines or recombinant protein controls.
Overall, CDO1 antibodies serve as essential reagents in both basic research and clinical studies, contributing to advances in understanding metabolic disorders, cancer biology, and therapeutic target discovery.